KYNB
MaterialsKyntra Bio Inc
$7.12+0.02 (+0.28%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving KYNB Today?
No stock-specific AI insight has been generated for KYNB yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$29M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume4K
Avg Volume (10D)—
Shares Outstanding4.0M
KYNB News
19 articles- Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 7, 2026
- Kyntra Bio to Report First Quarter 2026 Financial ResultsYahoo Finance·May 4, 2026
- Replays from RedChip's Biotech Investor Conference Now AvailableYahoo Finance·Apr 20, 2026
- Kyntra Bio (KYNB) Upgraded to Buy: Here's What You Should KnowYahoo Finance·Apr 14, 2026
- RedChip's April 16 Virtual Investor Conference to Highlight Companies Driving the Next Wave of Biotech InnovationYahoo Finance·Apr 10, 2026
- Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare ConferenceYahoo Finance·Apr 8, 2026
- Kyntra Bio Inc (KYNB) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline with ...Yahoo Finance·Mar 17, 2026
- Kyntra Bio (KYNB) Q4 2025 Earnings Call TranscriptMotley Fool·Mar 16, 2026
- Kyntra Bio: Q4 Earnings SnapshotYahoo Finance·Mar 16, 2026
- Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 16, 2026
- Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Yahoo Finance·Mar 12, 2026
- Septerna, Inc. (SEPN) Reports Q4 Loss, Tops Revenue EstimatesYahoo Finance·Mar 9, 2026
- Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseYahoo Finance·Mar 9, 2026
- Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Mar 9, 2026
- Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026Yahoo Finance·Feb 23, 2026
- Kyntra Bio to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 17, 2026
- What sets FGEN apart? Diversification, ESG and growth opportunities - FGEN P5Yahoo Finance·Jan 21, 2026
- Where FGEN sees growth beyond wind and solar - FGEN P4Yahoo Finance·Jan 21, 2026
- Inside FGEN’s inflation-linked income and dividend strategy - FGEN P3Yahoo Finance·Jan 21, 2026
All 19 articles loaded
Price Data
Open$0.00
Previous Close$7.10
Day High$0.00
Day Low$0.00
52 Week High—
52 Week Low—
Fundamentals
Market Cap$29M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume4K
Avg Volume (10D)—
Shares Outstanding4.0M
About Kyntra Bio Inc
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
MaterialsPHARMACEUTICAL PREPARATIONS
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICPHARMACEUTICAL PREPARATIONS
CIK—
Composite FIGI—
Share Class FIGI—